Manipulating the microbiome to improve the efficacy of immunotherapy.
Authors: Gajewski T PMID: 27379811 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Clinical use of checkpoint inhibition in kidney cancer.
Authors: PMID: 27379812 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Resistance exercise training in patients with genitourinary cancers to mitigate treatment-related skeletal muscle loss.
Authors: Glass OK, Ramalingam S, Harrison MR Abstract The use of targeted therapies in patients with genitourinary malignancies has significantly improved outcomes. For example, androgen receptor (AR) pathway inhibitors have improved outcomes for patients with prostate cancer, and antiangiogenic agents have improved outcomes for those with kidney cancer. However, these advances have been accompanied by musculoskeletal side effects that manifest as physical dysfunction. Although the effects of androgen deprivation therapy on skeletal muscle are well-known, an additional concern is that the muscle loss associated wit...
Source: Clinical Advances in Hematology and Oncology - July 7, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Challenges of conducting clinical trials of natural products to combat cancer.
Authors: Paller CJ, Denmeade SR, Carducci MA Abstract Numerous drugs that the US Food and Drug Administration (FDA) has approved for use in cancer therapy are derived from plants, including taxanes such as paclitaxel and vinca alkaloids such as vinblastine. Dietary supplements are another category of natural products that are widely used by patients with cancer, but without the FDA-reviewed evidence of safety and efficacy--be it related to survival, palliation, symptom mitigation, and/or immune system enhancement-that is required for therapy approval. Nearly half of patients in the United States with cancer report ...
Source: Clinical Advances in Hematology and Oncology - July 7, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter From the Editor: When will we ever learn?
Authors: Cheson BD PMID: 27379940 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The role of microsatellite instability testing in management of colorectal cancer.
Authors: Sinicrope FA PMID: 27379941 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The Mediterranean diet in hypercoagulable states and cancer.
Authors: Martínez-González MA PMID: 27379942 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in breast cancer from the 2016 American Society of Clinical Oncology Annual Meeting.
Authors: Rugo HS PMID: 27379943 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Management of invasive Aspergillosis in acute myelogenous leukemia.
Authors: Medeiros BC PMID: 27379944 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Current insights into the impact of dihydropyrimidine dehydrogenase deficiency in patients receiving treatment with 5-fluorouracil.
Authors: Diasio RB PMID: 27379945 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Update on the biology and management of neuroendocrine prostate cancer.
Authors: Beltran H PMID: 27379946 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer.
Authors: Zhang B, Hurvitz S Abstract Long-term outcomes for women with a diagnosis of human epidermal growth factor receptor 2 (HER2)-driven early-stage breast cancer have significantly improved since the advent of HER2-targeted therapy. Although the first studies in the early-stage setting focused on the adjuvant use of trastuzumab plus chemotherapy, clinical trials increasingly are using a neoadjuvant design to evaluate novel HER2-targeted therapies. Neoadjuvant therapy downstages locally advanced breast cancer, improves rates of breast conservation, and provides information regarding the responsiveness of a canc...
Source: Clinical Advances in Hematology and Oncology - July 7, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
Authors: Varma G, Johnson TP, Advani RH Abstract The development of Bruton's tyrosine kinase (BTK) inhibitors and their introduction into clinical practice represent a major advance in the treatment of chronic lymphocytic leukemia (CLL) and other B-cell lymphomas. Although ibrutinib is the only BTK inhibitor that has been approved by the US Food and Drug Administration, several others are under investigation. Ibrutinib is currently approved for use in relapsed/refractory CLL, CLL with 17p deletion (del[17p]), relapsed or refractory mantle cell lymphoma, and Waldenström macroglobulinemia. Although it is clear t...
Source: Clinical Advances in Hematology and Oncology - July 7, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter From the Editor: Moonshot medicine.
Authors: Cheson BD PMID: 27166600 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The science of checkpoint inhibition in kidney cancer.
Authors: PMID: 27166601 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Blastic plasmacytoid dendritic cell neoplasm.
Authors: Pemmaraju N PMID: 27166602 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Biomarkers for hepatocellular carcinoma.
Authors: Roberts LR PMID: 27166603 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Tumor and T-cell metabolism: new insights into melanoma therapy.
Authors: Delgoffe GM PMID: 27166604 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

HER2 testing in metastatic colorectal cancer: ready for prime time?
Authors: Hurwitz HI PMID: 27166605 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Novel approaches to delivering value in oncology drugs.
Authors: Miller S PMID: 27166606 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Approach to the surgical management of resectable gastric cancer.
Authors: Quadri HS, Hong YK, Al-Refaie WB Abstract The rates of gastric cancer, which is the third leading cause of cancer-related deaths worldwide, vary depending on geographic location. Margin-negative gastrectomy and adequate lymphadenectomy (removal of ≥15 lymph nodes) are the cornerstones of multimodal treatment for operable gastric cancer. Diagnostic laparoscopy should be included in the armamentarium for newly diagnosed gastric cancer in order to overcome the limitations of cross-sectional imaging in identifying sub-radiographic hepatic or peritoneal metastases. The benefit of surgical therapy is enhanced...
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Neoadjuvant chemotherapy for advanced epithelial ovarian cancer.
This article reviews the current literature on the use of neoadjuvant chemotherapy as a treatment strategy for patients with advanced epithelial ovarian cancer. PMID: 27166608 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Hem/Onc News.
Authors: Schuyler D PMID: 27166609 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Interim Results From ERADICATE: An Open-Label Phase 2 Study of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Castration-Resistant Prostate Cancer Subjects With Symptomatic Bone Metastases.
Authors: PMID: 27167841 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Challenging Cases Panel Discussion: Case #3.
Discussion: Case #3. Clin Adv Hematol Oncol. 2016 Apr;14 Suppl 5(4):8-9 Authors: PMID: 27167842 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Radium-223 (Ra-223) Re-Treatment (Re-tx): First Experience From an International, Multicenter, Prospective Study in Patients (Pts) With Castration-Resistant Prostate Cancer and Bone Metastases (mCRPC).
Authors: PMID: 27167843 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Survival Results From STAMPEDE (NCT00268476).
Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Survival Results From STAMPEDE (NCT00268476). Clin Adv Hematol Oncol. 2016 Apr;14 Suppl 5(4):11-13 Authors: PMID: 27167844 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Differential Side Effects Profile in mCRPC Patients Treated With Abiraterone or Enzalutamide: A Meta-Analysis of Randomized Controlled Trials.
Authors: PMID: 27167845 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Phase II Clinical Study of Radium-223 Chloride (BAY 88-8223) in Japanese Patients With Symptomatic Castration-Resistant Prostate Cancer (CRPC) With Bone Metastases.
Authors: PMID: 27167846 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in Metastatic Prostate Cancer From the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: Commentary.
Authors: Shore ND PMID: 27167847 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Current Concepts in the Management of GEP-NETs: Introduction.
Authors: Iyer R PMID: 27167990 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Cases in the Management of NETs: Focus on Sequencing Somatostatin Analogs.
Authors: Iyer R PMID: 27167991 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Cases in the Management of GEP-NETs: The Use of Surgery, an Underutilized Option in the Management of Advanced-Stage NETs.
Authors: Boudreaux JP PMID: 27167992 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Cases in the Management of GEP-NETs: Combination Regimens.
Authors: Braiteh F PMID: 27167993 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Tumor Growth Rate (TGR) as an Indicator of Antitumor Activity With Lanreotide Autogel/Depot (LAN) Versus Placebo (Pbo) in Intestinal/Pancreatic NET: Post Hoc Analysis of CLARINET Data.
Authors: PMID: 27168103 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

NETTER-1 Phase III in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-DOTATATE: Efficacy and Safety Results.
Authors: PMID: 27168104 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Budget Impact of Somatostatin Analogs (SSAs) as Treatment for Metastatic Gastroenteropancreatic Neuroendocrine Tumors (mGEP-NETs) in US Hospitals.
Authors: PMID: 27168105 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety From a RADIANT-4 Subgroup Analysis.
Authors: PMID: 27168106 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Interim Results on the Influence of Lanreotide on Uptake of [68Ga]-DOTATATE in Patients With Metastatic or Unresectable NET: No Evidence for Discontinuation of Lanreotide Before [68Ga]-DOTATATE PET/CT.
Authors: PMID: 27168107 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Pharmacokinetic (PK) Differences Between Subcutaneous and Intramuscular Administration of Lanreotide: Results From a Phase I Study.
Authors: PMID: 27168108 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in GEP-NETs From the 13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease: Commentary.
Authors: Iyer R, Hatoum H PMID: 27168109 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Initiation of Treatment in Chronic Lymphocytic Leukemia.
Authors: Pagel JM PMID: 27168202 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Evolving Frontline Treatment in Chronic Lymphocytic Leukemia.
Authors: Coutre SE PMID: 27168203 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Targeted Agents for the Frontline Management of Chronic Lymphocytic Leukemia.
Authors: Burger JA PMID: 27168204 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Discussion: Managing Risk When Using Idelalisib.
Authors: Coutre SE, Burger JA, Pagel JM PMID: 27168205 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Initial Treatment of Progressive Differentiated Thyroid Cancer.
Authors: Tuttle RM PMID: 27168341 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Sequencing of Tyrosine Kinase Inhibitors in Progressive Differentiated Thyroid Cancer.
Authors: Brose MS PMID: 27168342 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Best Use of the Tyrosine Kinase Inhibitors in Progressive Differentiated Thyroid Cancer: Discussion.
Discussion. Clin Adv Hematol Oncol. 2016 May;14 Suppl 9(5):12-13 Authors: Tuttle RM, Brose MS PMID: 27168343 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 12, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter From the Editor: The Children Act.
Authors: Cheson BD PMID: 27057660 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The impact of value-based insurance design on oncology drugs.
Authors: Fendrick AM PMID: 27057661 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 10, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research